Israeli startup Haptoguard, which has developed a kit to predict and prevent cardiovascular complications from diabetes, has commenced a $5.5 million financing round.
The kit can predict complications involving the kidneys, eyes and heart resulting from diabetes, through a simple blood test. The results help determine the treatment patients need.
Haptoguard was established under the auspices of BioRap, which operates under Haifa's Technion University. BioRap serves as a center to develop commercial applications for biotechnological research done at the university.